Literature DB >> 2012764

A comparison of sickle cell syndromes in northern Greece.

J Christakis1, N Vavatsi, H Hassapopoulou, M Angeloudi, M Papadopoulou, D Loukopoulos, J S Morris, B E Serjeant, G R Serjeant.   

Abstract

Haematological and clinical characteristics have been examined in 30 patients with homozygous sickle cell (SS) disease, 28 with sickle cell-beta zero thalassaemia, and 21 with sickle cell-beta+ thalassaemia. The latter could be divided into three groups on their molecular basis and HbA levels, four subjects with an IVS-2 nt 745 mutation having 3-6% HbA (designated S beta+ thalassaemia type I), 14 subjects with an IVS-1 nt 110 mutation having 8-15% HbA (designated S beta+ thalassaemia type II), and three subjects with an IVS-1 nt 6 mutation having 20-25% HbA (designated S beta+ thalassaemia type III). Comparisons were conducted between SS disease, S beta zero thalassaemia, and S beta+ thalassaemia type II. Compared to SS disease, both thalassaemia syndromes had higher HbA2 levels and red cell counts and lower mean cell haemoglobin content (MCHC), mean cell volume (MCV) and MCH, and S beta zero thalassaemia had higher HbF and reticulocyte counts. Compared to S beta zero thalassaemia, S beta+ thalassaemia had a higher haemoglobin and MCHC. Clinically, persistence of splenomegaly was more common in S beta zero and S beta+ thalassaemia type II compared to SS disease. Few significant differences occurred between SS disease, S beta zero and S beta+ thalassaemia type II in Northern Greece suggesting that the 8-15% HbA in the latter condition was insufficient to modify the clinical course.

Entities:  

Mesh:

Year:  1991        PMID: 2012764     DOI: 10.1111/j.1365-2141.1991.tb08589.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Fatal bone marrow embolism in a patient with sickle cell beta + thalassaemia.

Authors:  Y Zaidi; M Sivakumaran; C Graham; R M Hutchinson
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

2.  Clinical and genetic ancestry profile of a large multi-centre sickle cell disease cohort in Brazil.

Authors:  Anna B F Carneiro-Proietti; Shannon Kelly; Carolina Miranda Teixeira; Ester C Sabino; Cecilia S Alencar; Ligia Capuani; Tassila P Salomon Silva; Aderson Araujo; Paula Loureiro; Cláudia Máximo; Clarisse Lobo; Miriam V Flor-Park; Daniela O W Rodrigues; Rosimere A Mota; Thelma T Gonçalez; Carolyn Hoppe; João E Ferreira; Mina Ozahata; Grier P Page; Yuelong Guo; Liliana R Preiss; Donald Brambilla; Michael P Busch; Brian Custer
Journal:  Br J Haematol       Date:  2018-07-19       Impact factor: 6.998

3.  Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics.

Authors:  André R Belisário; Anna B Carneiro-Proietti; Ester Cerdeira Sabino; Aderson Araújo; Paula Loureiro; Cláudia Máximo; Miriam V Flor-Park; Daniela D O W Rodrigues; Mina Cintho Ozahata; Christopher McClure; Rosimere Afonso Mota; Isabel C Gomes Moura; Brian Custer; Shannon Kelly
Journal:  Hemoglobin       Date:  2020-03-16       Impact factor: 0.849

4.  Successful Treatment of Acute Chest Syndrome with Manual Exchange Transfusion in a Patient with Sickle Beta+-thalassemia.

Authors:  Akihiro Kawahara; Takehiko Morioka; Yuichiro Otani; Keishi Kanno; Taro Edahiro; Noriyasu Fukushima; Sachi Nagasaka; Mika Housai; Masaki Kakimoto; Naoki Tsuji; Shuntaro Asano; Yuka Kikuchi; Tomoki Kobayashi; Daisuke Miyamori; Ryoko Ishida; Kazuki Kimura; Nobusuke Kishikawa; Masafumi Mizooka; Tatsuo Ichinohe; Susumu Tazuma
Journal:  Intern Med       Date:  2019-02-01       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.